The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

Denis Malvy (1, 2) , Anne-Marie Taburet (3) , Xavier de Lamballerie (4) , France Mentré (5) , Fabrice Extramiana (6, 7)

1 BPH - Bordeaux population health
2 Department for Infectious and Tropical Diseases [Bordeaux]
3 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
4 UVE - Unité des Virus Emergents
5 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
6 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
7 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases

Domaines: Pharmacologie; Maladies infectieuses; Virologie

Denis Malvy, Anne-Marie Taburet, Xavier de Lamballerie, France Mentré, Fabrice Extramiana. The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Neglected Tropical Diseases, 2020, 14 (6), pp.e0008259. ⟨10.1371/journal.pntd.0008259⟩. ⟨inserm-02910920⟩